Etienne Regulier
Overview
Explore the profile of Etienne Regulier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
863
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Burke J, Hunsche E, Regulier E, Nagao M, Buzinec P, Iii W
Am J Manag Care
. 2015 Mar;
21(3 Suppl):s47-58.
PMID: 25734573
Objectives: This study assessed pulmonary hypertension (PH)-related hospitalizations, including readmissions, among US patients with pulmonary arterial hypertension (PAH), a rare disease characterized by high morbidity and premature mortality. Study Design:...
2.
Taylor D, Moser R, Regulier E, Breuillaud L, Dixon M, Beesen A, et al.
J Neurosci
. 2013 Feb;
33(6):2313-25.
PMID: 23392662
We previously demonstrated that sodium butyrate is neuroprotective in Huntington's disease (HD) mice and that this therapeutic effect is associated with increased expression of mitogen-activated protein kinase/dual-specificity phosphatase 1 (MKP-1/DUSP1)....
3.
Rudinskiy N, Kaneko Y, Beesen A, Gokce O, Regulier E, Deglon N, et al.
J Neurochem
. 2009 Aug;
111(2):460-72.
PMID: 19686238
Hippocalcin is a neuronal calcium sensor protein previously implicated in regulating neuronal viability and plasticity. Hippocalcin is the most highly expressed neuronal calcium sensor in the medium spiny striatal output...
4.
Weiss A, Abramowski D, Bibel M, Bodner R, Chopra V, DiFiglia M, et al.
Anal Biochem
. 2009 Aug;
395(1):8-15.
PMID: 19664996
The genetic mutation causing Huntington's disease is a polyglutamine expansion in the huntingtin protein where more than 37 glutamines cause disease by formation of toxic intracellular fragments, aggregates, and cell...
5.
Runne H, Regulier E, Kuhn A, Zala D, Gokce O, Perrin V, et al.
J Neurosci
. 2008 Sep;
28(39):9723-31.
PMID: 18815258
Gene expression changes are a hallmark of the neuropathology of Huntington's disease (HD), but the exact molecular mechanisms of this effect remain uncertain. Here, we report that in vitro models...
6.
Lo Bianco C, Shorter J, Regulier E, Lashuel H, Iwatsubo T, Lindquist S, et al.
J Clin Invest
. 2008 Aug;
118(9):3087-97.
PMID: 18704197
Parkinson disease (PD) is characterized by dopaminergic neurodegeneration and intracellular inclusions of alpha-synuclein amyloid fibers, which are stable and difficult to dissolve. Whether inclusions are neuroprotective or pathological remains controversial,...
7.
Alves S, Regulier E, Nascimento-Ferreira I, Hassig R, Dufour N, Koeppen A, et al.
Hum Mol Genet
. 2008 Apr;
17(14):2071-83.
PMID: 18385100
Machado-Joseph disease (MJD) is a fatal, dominant neurodegenerative disorder. MJD results from polyglutamine repeat expansion in the MJD-1 gene, conferring a toxic gain of function to the ataxin-3 protein. In...
8.
Weiss A, Klein C, Woodman B, Sathasivam K, Bibel M, Regulier E, et al.
J Neurochem
. 2007 Nov;
104(3):846-58.
PMID: 17986219
A CAG-repeat gene expansion translated into a pathogenic polyglutamine stretch at the N-terminus of huntingtin triggers Huntington's Disease. Mutated huntingtin is predicted to adopt toxic properties mainly if aggregation-prone N-terminal...
9.
Charvin D, Roze E, Perrin V, Deyts C, Betuing S, Pages C, et al.
Neurobiol Dis
. 2007 Oct;
29(1):22-9.
PMID: 17905594
Huntington's disease (HD) results from an abnormal polyglutamine extension in the N-terminal region of the huntingtin protein. This mutation causes preferential degeneration of striatal projection neurons. We previously demonstrated, in...
10.
Runne H, Kuhn A, Wild E, Pratyaksha W, Kristiansen M, Isaacs J, et al.
Proc Natl Acad Sci U S A
. 2007 Aug;
104(36):14424-9.
PMID: 17724341
Highly quantitative biomarkers of neurodegenerative disease remain an important need in the urgent quest for disease-modifying therapies. For Huntington's disease (HD), a genetic test is available (trait marker), but necessary...